Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Create alerts with multiple filters including highs/low, comparative values, and turning points. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Spero Therapeutics Inc (SPRO)

Spero Therapeutics Inc (SPRO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 25,476
  • Shares Outstanding, K 32,822
  • Annual Sales, $ 18,260 K
  • Annual Income, $ -89,760 K
  • 60-Month Beta 1.95
  • Price/Sales 1.48
  • Price/Cash Flow N/A
  • Price/Book 0.43
Trade SPRO with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -3.24
  • Most Recent Earnings -1.01 on 05/16/22
  • Next Earnings Date 08/10/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 609.93% ( +296.40%)
  • Historical Volatility 73.98%
  • IV Percentile 97%
  • IV Rank 74.41%
  • IV High 798.57% on 06/28/22
  • IV Low 61.29% on 12/22/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 170
  • Volume Avg (30-Day) 13
  • Put/Call OI Ratio 0.38
  • Today's Open Interest 1,663
  • Open Int (30-Day) 2,302

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.88
  • Number of Estimates 2
  • High Estimate -0.86
  • Low Estimate -0.90
  • Prior Year -0.63
  • Growth Rate Est. (year over year) -39.68%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6801 +14.69%
on 08/02/22
1.0000 -22.00%
on 08/09/22
-0.0446 (-5.41%)
since 07/08/22
3-Month
0.6801 +14.69%
on 08/02/22
1.8200 -57.14%
on 05/16/22
-0.9800 (-55.68%)
since 05/10/22
52-Week
0.6801 +14.69%
on 08/02/22
19.8700 -96.07%
on 09/28/21
-13.1200 (-94.39%)
since 08/10/21

Most Recent Stories

More News
Spero Therapeutics to Provide Business Update and Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022

CAMBRIDGE, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that it will host a conference call and live...

SPRO : 0.8006 (+2.64%)
SHAREHOLDER ALERT FILING DEADLINE TODAY: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Spero Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - SPRO

/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Spero Therapeutics, Inc. ("Spero" or the "Company") (NASDAQ: SPRO)...

SPRO : 0.8006 (+2.64%)
Bronstein, Gewirtz & Grossman, LLC Reminds Spero Therapeutics, Inc. (SPRO) Shareholders of Class Action Deadline and Last Few Hours to Actively Participate

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Spero Therapeutics, Inc. (“Spero” or the “Company”) (NASDAQ: SPRO)...

SPRO : 0.8006 (+2.64%)
FINAL DEADLINE ALERT: The Schall Law Firm Encourages Investors in Spero Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

/PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Spero Therapeutics, Inc....

SPRO : 0.8006 (+2.64%)
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Spero Investors of a Lead Plaintiff Deadline of July 25, 2022

/PRNewswire/ -- Attention Spero Therapeutics, Inc. ("Spero") (NASDAQ: SPRO) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit...

SPRO : 0.8006 (+2.64%)
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Spero Therapeutics, Inc. (SPRO)

The Law Offices of Frank R. Cruz reminds investors of the upcoming July 25, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Spero Therapeutics,...

SPRO : 0.8006 (+2.64%)
Pomerantz Law Firm Announces the Filing of a Class Action Against Spero Therapeutics, Inc. and Certain Officers - SPRO

/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Spero Therapeutics, Inc. ("Spero" or the "Company") (NASDAQ: SPRO)...

SPRO : 0.8006 (+2.64%)
SPRO Investors Have Opportunity to Lead Spero Therapeutics, Inc. Securities Fraud Lawsuit

/PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action...

SPRO : 0.8006 (+2.64%)
SPRO LAWSUIT ALERT: Levi & Korsinsky Notifies Spero Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

/PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Spero Therapeutics, Inc. ("Spero" or the "Company") (NASDAQ: SPRO) of a class action securities...

SPRO : 0.8006 (+2.64%)
SPRO FINAL DEADLINE ALERT: ROSEN, A LEADING NATIONAL FIRM, Encourages Spero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SPRO

/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Spero Therapeutics, Inc. (NASDAQ: SPRO) between...

SPRO : 0.8006 (+2.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Spero Therapeutics Inc. is a multi-asset, clinical-stage biopharmaceutical company. It focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections. Spero Therapeutics Inc. is based in CAMBRIDGE, United States.

See More

Key Turning Points

3rd Resistance Point 1.1575
2nd Resistance Point 1.0787
1st Resistance Point 0.9275
Last Price 0.8006
1st Support Level 0.6975
2nd Support Level 0.6187
3rd Support Level 0.4675

See More

52-Week High 19.8700
Fibonacci 61.8% 12.5395
Fibonacci 50% 10.2751
Fibonacci 38.2% 8.0106
Last Price 0.8006
52-Week Low 0.6801

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar